Last reviewed · How we verify
GBR 900
At a glance
| Generic name | GBR 900 |
|---|---|
| Sponsor | Glenmark Pharmaceuticals Ltd. India |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer (PHASE1, PHASE2)
- Safety and Tolerability of GBR 900 in a Single Ascending Dose Study in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GBR 900 CI brief — competitive landscape report
- GBR 900 updates RSS · CI watch RSS
- Glenmark Pharmaceuticals Ltd. India portfolio CI